Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110786 | 0.80 | MAOB (0.46) | CGASMAOBTRPA1CYP3A4ALDH1A1 | |
| SCHEMBL3529271 | 0.80 | MAOB (0.46) | MAOBTRPA1CYP3A4ALDH1A1MEN1 | |
| SCHEMBL5744783 | 0.77 | MAOB (0.43) | CGASMAOBTRPA1CYP3A4ALDH1A1 | |
| SCHEMBL2636861 | 0.76 | MAOB (0.46) | MAOBTRPA1CYP3A4ALDH1A1MEN1 | |
| SCHEMBL5852202 | 0.75 | ALOX5 (0.44) | CGASMAOBTRPA1CYP3A4ALDH1A1 | |
| SCHEMBL2911478 | 0.75 | MAOB (0.42) | CGASMAOBTRPA1CYP3A4ALDH1A1 | |
| SCHEMBL69624 | 0.74 | MAOB (0.59) | MAOBTRPA1CYP3A4ALDH1A1MEN1 | |
| SCHEMBL4662662 | 0.71 | CYP3A4 (0.44) | MAOBCYP3A4ALDH1A1TSHRHPGD | |
| SCHEMBL3921025 | 0.71 | CYP3A4 (0.44) | MAOBCYP3A4ALDH1A1TSHRHPGD | |
| SCHEMBL3272704 | 0.71 | ALOX5 (0.44) | CGASMAOBTRPA1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805138-B1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-7579378-B2 | Sulfonamido compounds that antagonize the vanilloid TRPV1 receptor | PHARMESTE S.R.L. (IT) | 2009-08-25 | — | — | US | disclosed |
| US-20090118374-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE S.R.L. (IT) | 2009-05-07 | — | — | US | disclosed |
| EP-1805138-B1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE SRL (IT) | 2008-03-19 | — | — | EP | disclosed |
| EP-1805138-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | Pharmeste S.r.l. (IT) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045498-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE S.R.L. (IT) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118374-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | TRPV1, TRPA1, TRPV4 | CGAS 2506/4885MAOB 2647/4885TRPA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.